In an effort to raise awareness for type 1 diabetes, one of the most costly chronic diseases in the world, JDRF co-hosted a two-day diabetes forum at the 2011 BIO International Convention, the first forum that BIO—the largest global event for the biotechnology industry—has ever dedicated to a specific disease.
JDRF’s senior research staff actively participated as moderators in the six sessions, where leading policymakers, scientists, CEOs, and newsmakers from all over the world showcased key opportunities and developments in type 1 and type 2 diabetes, including the latest research in innovative therapies, vaccines, and biomarkers. The forum also addressed the global burden of diabetes on the healthcare system, as well as novel financing approaches to support opportunities that originate in academic institutions.
JDRF also took part in the BIO Business Forum. This event is a unique platform for biotechnology and pharmaceutical companies, academic research institutions, and investors from around the world to gather and discuss strategic opportunities and forge discussions on developing products and therapies that will ultimately benefit the lives of the millions of Americans living with diabetes.
JDRF’s participation in the BIO convention was covered by C-SPAN’s Washington Journal, featuring Richard A. Insel, M.D., chief scientific officer at JDRF, and Scott Whitaker, chief operating officer of BIO International. A three-hour radio media tour was also arranged for Aaron J. Kowalski, Ph.D., assistant vice president for treatment therapies at JDRF, and Julia L. Greenstein, Ph.D., assistant vice president for cure therapies, to discuss the diabetes forum.